Clinical Trials
70 trialsNCT02112916 2026-05-27
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00092222 2026-05-22
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00734877 2026-05-22
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT00869232 2026-05-22
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05514990 2026-05-13
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
Phase 1/2 Active not recruiting
NCT06169215 2026-05-13
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00871013 2026-05-11
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT04181827 2026-05-11
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04722146 2026-05-08
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04923893 2026-05-08
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05083169 2026-05-08
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06577025 2026-05-08
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT03319667 2026-05-04
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT04653246 2026-04-30
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04246047 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868667 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT05392946 2026-04-21
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Phase 1/2 Active not recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03763162 2026-04-15
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01695941 2026-04-13
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01861314 2026-04-13
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04133636 2026-04-13
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT02773030 2026-03-20
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT06353022 2026-03-17
IFm2022-01
Nantes University Hospital
Phase 2 Active not recruiting
NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04802356 2026-03-05
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
PETHEMA Foundation
Phase 2 Active not recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT03589222 2026-02-27
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
PETHEMA Foundation
Phase 2 Active not recruiting
NCT00378105 2026-02-24
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04754945 2026-02-18
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Phase 1 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT04751877 2026-02-10
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
Phase 3 Active not recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting